Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Clinical trials in menopause.

Marko KI, Simon JA.

Menopause. 2017 Oct 4. doi: 10.1097/GME.0000000000000978. [Epub ahead of print]

PMID:
28953214
2.

The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.

Parish SJ, Gillespie JA.

Postgrad Med. 2017 Apr;129(3):340-351. doi: 10.1080/00325481.2017.1281083. Epub 2017 Jan 30. Review.

PMID:
28132583
3.

Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.

Mohammed K, Abu Dabrh AM, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, Montori VM, Faubion SS, Murad MH.

J Clin Endocrinol Metab. 2015 Nov;100(11):4012-20. doi: 10.1210/jc.2015-2237. Review.

PMID:
26544651
4.

From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition.

Valera MC, Gourdy P, Trémollières F, Arnal JF.

Maturitas. 2015 Nov;82(3):274-7. doi: 10.1016/j.maturitas.2015.07.012. Epub 2015 Jul 26. Review.

PMID:
26261036
5.

Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.

Bassuk SS, Manson JE.

Ann Epidemiol. 2015 Mar;25(3):193-200. doi: 10.1016/j.annepidem.2014.11.004. Epub 2014 Nov 13.

6.

Fish intake and venous thromboembolism: a Danish follow-up study.

Severinsen MT, Overvad K, Andersen VL, Tjønneland A, Schmidt EB, Kristensen SR.

Thromb Res. 2014 Mar;133(3):352-6. doi: 10.1016/j.thromres.2013.12.018. Epub 2013 Dec 31.

PMID:
24423887
7.

Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy.

McBane SE, Borgelt LM, Barnes KN, Westberg SM, Lodise NM, Stassinos M.

Pharmacotherapy. 2014;34(4):410-23. doi: 10.1002/phar.1394. Epub 2014 Jan 4.

PMID:
24390902
8.

Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification.

Bassuk SS, Manson JE.

Clin Chem. 2014 Jan;60(1):68-77. doi: 10.1373/clinchem.2013.202556. Review.

9.

Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative.

Howard BV, Rossouw JE.

Curr Opin Lipidol. 2013 Dec;24(6):493-9. doi: 10.1097/MOL.0000000000000022. Review.

10.

The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.

J Steroid Biochem Mol Biol. 2014 Jul;142:4-11. doi: 10.1016/j.jsbmb.2013.10.009. Epub 2013 Oct 27. Review.

PMID:
24172877
11.

Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials.

Canonico M, Plu-Bureau G, O'Sullivan MJ, Stefanick ML, Cochrane B, Scarabin PY, Manson JE.

Menopause. 2014 Mar;21(3):214-20. doi: 10.1097/GME.0b013e31829752e0.

12.

The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: comparative risks.

Hodis HN, Mack WJ.

J Am Geriatr Soc. 2013 Jun;61(6):1011-8. doi: 10.1111/jgs.12281. Epub 2013 May 20. Review.

PMID:
23692449
13.

Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.

Rossouw JE, Manson JE, Kaunitz AM, Anderson GL.

Obstet Gynecol. 2013 Jan;121(1):172-6. doi: http://10.1097/AOG.0b013e31827a08c8.

14.

Estrogen and progestogen effect on venous thromboembolism in menopausal women.

Archer DF, Oger E.

Climacteric. 2012 Jun;15(3):235-40. doi: 10.3109/13697137.2012.664401. Review.

PMID:
22612609
15.

Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.

Mueck AO.

Climacteric. 2012 Apr;15 Suppl 1:11-7. doi: 10.3109/13697137.2012.669624. Review.

PMID:
22432811
16.

What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.

Simon JA.

Climacteric. 2012 Apr;15 Suppl 1:3-10. doi: 10.3109/13697137.2012.669332. Review.

PMID:
22432810
17.

Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.

Davey DA.

Womens Health (Lond). 2012 Mar;8(2):169-89. doi: 10.2217/whe.12.1. Review.

PMID:
22375720
18.

Primary prevention of cardiovascular disease with HRT.

Maclaran K, Stevenson JC.

Womens Health (Lond). 2012 Jan;8(1):63-74. doi: 10.2217/whe.11.87. Review.

PMID:
22171776
19.

Benefits and risks during HRT: main safety issue breast cancer.

Mueck AO, Ruan X.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(2):105-16. doi: 10.1515/HMBCI.2011.014.

PMID:
25961246
20.

Hormonal influences on hemostasis in women.

Trigg DE, Wood MG, Kouides PA, Kadir RA.

Semin Thromb Hemost. 2011 Feb;37(1):77-86. doi: 10.1055/s-0030-1270074. Epub 2011 Jan 19. Review.

PMID:
21249605

Supplemental Content

Loading ...
Support Center